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Introduction
Cancer vaccines aiming to induce anti-tumor immune
responses are generally considered most effective in an
environment with minimal residual disease, due to the
immunosuppressive effects exerted by most cancers. We
hypothesized that appropriately activated autologous den-
dritic cells (DCVax®-Direct) may be able to overcome this
suppressive environment through the production of
inflammatory cytokines and through the activation of sig-
nal transduction pathways that condition the dendritic
cells for completion of the maturation processes even after
intratumoral injection.
Methods
A Phase I trial that enrolled 36 patients with diverse
solid tumor cancers. Three intratumoral DCVax-Direct
injections were given at Day 0, 7 and 14, followed by
additional injections at weeks 8, 16 and 32. Patients
were followed for safety parameters, for tumor response
using appropriate imaging, and for pathological evalua-
tion of tumor tissue from serial biopsies. Evaluation of
circulating immune cell populations as well as circulat-
ing cytokines is in progress.
Results
Recurrent low to moderate fevers were seen in most
patients following DCVax-Direct administration. Sub-
stantial apparent increases in tumor size, were observed
on CT or PET scans in the majority of patients. Tumor
biopsies of injected lesions demonstrated extensive tumor
necrosis, as well as large immune cell accumulations,
containing CD4+ and CD8+ T cells and other immune
cells. In addition, these biopsies often showed paucity of
tumor cells or, in some cases, no tumor cells were
detected in the biopsies. In the one patient assessed to
date for circulating immune cells, a normalization of the
CD4:CD8 ratio was seen. Analysis of longer-term imaging
data to assess tumor response is in progress.
Conclusions
Intratumoral injection of activated, autologous dendritic
cells is safe and feasible. The accumulation of immune
cells in tumor biopsies suggests that these injections
have the potential to successfully change the tumor
microenvironment from immunosuppressive to one that
is conducive to the induction of anti-tumor immune
responses. Normalization of the CD4:CD8 T cell ratio in
circulation demonstrates the potential for systemic
effects of this novel therapeutic approach.
ClinicalTrials.gov Identifier: NCT01882946
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